Developing Story
US Patent Competitiveness Erosion – Judicially-Created Obviousness-Type Double Patenting Doctrine
IPWatchdog reporting argues the U.S. is uniquely harmed by a judicially-created obviousness-type double patenting (ODP) doctrine that truncates patent terms across related families — a practice not replicated in Europe, China, or most other jurisdictions. The doctrine is judge-made, limiting legislative remedies, and intersects with ongoing PTAB and patent enforcement debates. This is a developing policy narrative with acute implications for pharmaceutical and biotech patent portfolios.
Importance: 72%Confidence: 78%Mentions: 1Updated: June 16, 2026
## US Patent Competitiveness Erosion – Judicially-Created Obviousness-Type Double Patenting Doctrine
### Overview
IPWatchdog reporting (June 14, 2026) argues that the United States is uniquely disadvantaged globally due to judicially-created patent doctrine — specifically, obviousness-type double patenting (ODP) — which forces patent term truncation on related patent families in a manner no other major jurisdiction replicates. This is a developing narrative in the context of the broader U.S. patent competitiveness debate tracked in existing wiki pages on PTAB institution rate decline and patent enforcement asymmetry.
### Core Legal Issue
According to IPWatchdog (June 14, 2026):
- The U.S. is the **only country** where the judiciary imposes patent term truncation across unrelated patent families via ODP doctrine
- **Europe, China, and most other nations** apply a "novelty only" standard for applications filed before publication of an earlier-filed patent, and a "novelty and inventive step" standard for applications filed after publication — a framework IPWatchdog characterizes as working "well" (IPWatchdog, June 14, 2026)
- U.S. ODP doctrine is judge-made, not statutory, which limits legislative remedies and concentrates the fix in either judicial reversal or congressional action
### Relationship to Existing Tracked Issues
This narrative intersects with:
- **Ex Parte Baurin (PTAB)**: PTAB is actively reconsidering ODP standards in the post-grant context (existing wiki page)
- **IPR Institution Rate Decline**: Broader patent holder disadvantage in U.S. post-grant proceedings
- **Patent Enforcement Asymmetry**: U.S. patent holders face structural disadvantages relative to foreign competitors whose home jurisdictions provide stronger patent protection
### Strategic Implications
- **Pharma & biotech**: ODP doctrine most acutely affects pharmaceutical patent families, where continuation strategies are essential; truncated terms can eliminate years of exclusivity
- **Patent prosecution attorneys**: Portfolio strategy must account for U.S.-specific terminal disclaimer requirements and the risk of invalidating related patents through ODP challenges
- **IP policy advocates**: The judicially-created nature of the doctrine is both the problem and the potential solution — a Federal Circuit en banc ruling or SCOTUS review could resolve it without legislation
- **Multinational filers**: Companies filing in both the U.S. and Europe/China face asymmetric protection terms that may affect where R&D investment is directed
### Open Questions
- Whether the Federal Circuit will take up ODP doctrine reform en banc following Ex Parte Baurin
- Whether Congress will act to codify a statutory double-patenting standard aligned with international norms
- How ODP interacts with patent term adjustment (PTA) and patent term extension (PTE) in pharmaceutical contexts